key: cord-0983264-c2jagjmf
authors: Chan, Wai Y.; Ramli Hamid, Marlina T.; Lim, Yi T.; Ng, Ching C.; Gowdh, Nadia F.M.; Rahmat, Kartini
title: Pulmonary Complications of COVID-19: A case report
date: 2022-02-28
journal: Sultan Qaboos Univ Med J
DOI: 10.18295/squmj.4.2021.070
sha: 7e7fe2cba12434b87da17911b5c6f3ae7e399115
doc_id: 983264
cord_uid: c2jagjmf

Rapid evolution of pulmonary complications associated with severe COVID-19 pneumonia often pose a management challenge to clinicians especially in the critical care setting. Serial chest imaging enable clinicians to better monitor disease progression and identify potential complications early which may decrease the mortality and morbidity associated with COVID-19. We report a 69-year-old male patient with severe COVID-19 pneumonia who presented to a tertiary referral centre in Kuala Lumpur, Malaysia, in 2020 with multiple pulmonary complications including lung cavitation, bronchopleural fistula, pneumothorax, pneumomediastinum, subcutaneous emphysema and acute pulmonary embolism. Unfortunately, the patient died one month after admission. COVID-19 patients may develop pulmonary complications due to a combination of direct viral lung damage, hypoxaemia and high stress ventilation. Awareness of COVID-19 complications can prompt early diagnosis and timely management to reduce morbidity and mortality.

of high-grade fever and occasional dry cough. He had recently attended a mass gathering, however there was no known history of close contact with a confirmed or probable COVID-19 positive case. Clinical examination revealed an elevated body temperature of 38.5°C and bibasal lung crepitations on auscultation. Laboratory blood tests revealed a normal neutrophil count of 6.5 × 10 9 /L (normal range: 2.0-7.0 × 10 9 /L), borderline lymphocyte count of 1.14 × 10 9 /L (normal range: 1.0-3.0 × 10 9 /L), raised C-reactive protein of 137.6 mg/L (normal range: <5.0 mg/L) with high serum ferritin of 2,268 µg/L (normal range: 22.0-322.0 µg/L). The remaining blood investigations were normal. Screening tests for respiratory pathogens such as influenza A, influenza B, respiratory syncytial virus, legionella, mycoplasma pneumonia and chlamydia pneumonia were negative. SARS-CoV-2 was detected in the patient's oropharyngeal and nasopharyngeal swab specimen through real-time reverse-transcriptionpolymerase chain-reaction assay.

The CXR at presentation showed classic peripheral consolidations in both lower zones. On day three of hospitalisation (nine days after the onset of fever), the patient developed worsening dyspnoea despite escalation of oxygen support to a Venturi mask. He was then transferred to the intensive care unit (ICU) and was put on high flow nasal cannula (HFNC) noninvasive ventilatory support. No clinical improvement was seen despite optimum HFNC setting (fraction of inspired oxygen = 0.6, flow = 60 L/min). The patient was started on empirical intravenous ceftriaxone, azithromycin, hydroxychloroquine, lopinavir/ritonavir C ovid-19 emerged from wuhan, hubei Province, China in December 2019 and rapidly spread worldwide. Most affected patients have mild symptoms with good prognosis. However, WHO-China Joint Mission on Coronavirus Disease 2019 reported severe and critical diseases in 13.8% and 6.1% of patients, respectively. 1 Pneumonia is a common complication of COVID-19 infection, whilst acute respiratory distress syndrome (ARDS) is the most severe sequela. Presence of pleural effusion, lung cavitation and lymphadenopathy are associated with severe disease and often carry poorer prognosis. 2 Many studies have reported common COVID-19 chest manifestation on chest X-ray (CXR) and computed tomography (CT), however, studies that described chest complications on imaging are limited. Herein, we report a case of severe COVID-19 pneumonia, which progressed to multiple pulmonary complications including acute pulmonary embolism, pneumothorax, pneumomediastinum, extensive subcutaneous emphysema and ruptured lung cysts causing bronchopleural fistula. This case report aims to raise awareness of potential complications, spectrum of respiratory manifestations and sequelae of COVID-19 infection.

A 69-year-old male patient with underlying diabetes mellitus and hypertension presented to the emergency department at a tertiary referral centre in Kuala Lumpur, Malaysia in March 2020 with a 6-day history positive respiratory and blood culture results. CXR done on day 24 of illness demonstrated a new welldefined cystic lesion at the right lower zone [ Figure  2A ]. There was no pneumothorax in the right chest. The left pneumothorax and subcutaneous emphysema had improved. A follow-up CTPA showed residual right pulmonary artery emboli and a large cyst in the consolidated right middle lobe communicating with a and subcutaneous enoxaparin prophylaxis dose based on the best evidence at that point of time during the early phase of COVID-19 in Malaysia.

He remained tachypnoeic with a respiratory rate of >30/min and oxygen saturation of 88-92% with partial pressure oxygen of 51 mmHg on arterial blood gas analysis. The patient eventually required intubation and mechanical ventilation after six hours. Highresolution CT (HRCT) scan of his chest was done on the next day (day 10 of the illness) which revealed groundglass opacities (GGO) with consolidations and crazypaving patterns in both lung fields, predominantly in a subpleural distribution with approximately 50% total lung involvement. There was also gravity-dependent lung atelectasis in posterior lung bases bilaterally. No cystic lung lesions were noted in this initial CT. In view of worsening respiratory distress, the patient required mechanical ventilation with positive end-expiratory pressure averaging 10-14 cm H 2 O.

On day 18 of illness and approximately one week after commencement of mechanical ventilation, the patient developed worsening oxygenation and extensive subcutaneous emphysema at the neck, chest and abdominal regions. Immediate CXR and abdominal X-ray (AXR) showed left pneumothorax, pneumomediastinum as well as extensive subcutaneous emphysema [ Figures 1A and B ]. Positive D-dimer was also detected at the same time. An urgent CT pulmonary angiography (CTPA), which was performed on the same day, showed feft pneumothorax, pneumomediastinum, extensive subcutaneous emphysema and extraperitoneal emphysema extending from the pneumomediastinum were observed. No parenchymal or subpleural cysts were present. There were also worsening dependent consolidations in both lung fields [ Figures 1C and D]. A filling defect consistent with emboli in the right main pulmonary artery extending to the segmental arteries of the right middle and lower lobes as well as in the segmental branches of the left lower lobe pulmonary artery was also observed [ Figures 1E and F ]. Subsequently, a chest tube was inserted for the left pneumothorax and subcutaneous enoxaparin was upgraded to treatment dose in view of the pulmonary embolism diagnosis.

The patient was continued on mechanical ventilation due to difficult weaning. Possible development of superimposed bacterial infection could have contributed to the worsening respiratory status of the patient. Antibiotic treatment was escalated to intravenous (IV) meropenem and vancomycin on day 21 of illness; IV hydrocortisone 50 mg every six hours was initiated for septic shock. This was followed by the addition of IV trimethoprim/sulfamethoxazole as Stenotrophomonas maltophilia was found based on segmental bronchus [ Figures 2B and C ]. There were also multiple subpleural cysts, some communicating with each other in the right middle and lower lobes [ Figure 2D ]. At the time, it was postulated that these cysts were likely secondary to underlying severe COVID-19 lung changes. However, complication secondary to pulmonary infarct cannot be excluded. The next day, the patient developed right tension pneumothorax secondary to rupture of the lung cysts and an emergency right chest tube insertion was done [ Figures 3A and B] . Unfortunately, despite insertion of double chest tubes over the right lung, the pneumothorax persisted. Subsequently, blood pleurodesis was carried out but no clinical improvement was noted.

Throughout the patient's ICU stay, he required multiple cycles of prone positioning as rescue therapy to improve oxygenation. He also developed multiorgan failure requiring vasopressors and continuous renal replacement therapy. On day 24 of hospitalisation Table 1 ]. Informed consent for publication purposes was obtained from the patient's family member.

Chest imaging is indicated in COVID-19 patients for establishing a baseline for the patient's pulmonary condition, identification of cardiopulmonary comorbidities and for monitoring disease progression. In the event of clinical deterioration, imaging assessment helps to diagnose disease progression and acute cardiopulmonary complications such as pulmonary embolism, superimposed bacterial infection, heart failure or less commonly, complications such as pneumothorax and pneumomediastinum. 3, 4 Typical chest findings in COVID-19 patients show bilateral lung involvement with patchy or asymmetric diffuse air space opacities, predominantly in a peripheral, posterior distribution and mainly in the lower lobes. 5 In later stages of the disease, CT may show increased GGO, dispersed consolidation, reticular opacities, crazy-paving, bronchiectasis, pleural thickening, septal thickening and involvement of subpleural region. 2, 5 As the disease progresses, atypical CT features such as pleural effusion, cystic changes, pericardial effusion, nodules and lymphadenopathy may be present. 2, 5 In addition, complications such as pulmonary embolism, pneumothorax, pneumomediastinum and cavitation or cysts in COVID-19 positive patients have emerged which further elucidates the complexity in managing such patients. 4 COVID-19 pneumonia is described as a unique disease despite fulfilling most of the Berlin definition of ARDS. 6 The pathophysiology of this disease is attributed by a hyperimmune reaction of the host which results in massive vascular endothelial injury and alveolar epithelial cell damage. 7 In the current case, the patient had no history of smoking or underlying lung pathology. The initial viral infection may impose structural damage to alveoli, particularly at the subpleural regions where 'stress and strain' insult is the greatest. 2, 7, 8 This could possibly result in pneumatoceles or cysts in the subpleural areas of consolidation, as was seen in the current case. The development of lung cavitation is uncommon in COVID-19 positive patients and could occur secondary to direct lung damage caused by the virus, stress imposed by the mechanical ventilation or may also result from secondary bacterial or fungal infection. Possibility of secondary infection must be ruled out in the wake of development of lung cavitation in COVID-19 and appropriately managed to improve the patient outcome. The high stresses generated during mechanical ventilation can cause barotrauma leading to bronchial or alveolar rupture, which is evidenced by air leak detected as pneumothorax, pneumomediastinum and subcutaneous emphysema on imaging. 4, 5, 9 Furthermore, the current patient developed acute pulmonary embolism during the course of the illness, which further exacerbated the ventilation/perfusion imbalances. Klok et al. reported that pulmonary embolism is the most common thrombotic complication encountered in patients with COVID-19; 16-31% of pulmonary embolism are complicated by pulmonary infarction and cavitation complicates 4-7% of pulmonary infarctions. [10] [11] [12] [13] Infarcts with cavities are commonly single, right-sided and after 2 weeks is associated with a large area of consolidation. 14 Severe COVID-19 pneumonia is susceptible to both venous and arterial thromboembolism due to deranged coagulation, excessive inflammation, hypoxia and prolonged immobilisation. In addition, an increased D-dimer concentration at the time of admission is significantly associated with mortality. 10, 15 Hence, judicious use of anticoagulant therapy is prudent in patients with COVID-19 pneumonia in the absence of bleeding risk.

The current case highlights the imaging findings of multiple pulmonary complications in a patient with severe COVID-19 pneumonia. Widespread lung damage, hypoxaemia and high-stress ventilation may lead to severe manifestations as was seen in this case. Prompt recognition of these complications, cautious ventilation strategy and timely intervention targeted at the complications should be the direction of care for such patients to reduce morbidity and mortality. 

Report of the who-china joint mission on coronavirus disease 2019 (Covid-19)

Radiological findings from 81 patients with COVID-19 pneumonia in Wuhan, China: A descriptive study

The role of chest imaging in patient management during the COVID-19 pandemic: A multinational consensus statement from the Fleischner Society

Mediastinal emphysema, giant bulla, and pneumothorax developed during the course of COVID-19 pneumonia

Coronavirus disease 2019 (COVID-19): A systematic review of imaging findings in 919 patients

Acute respiratory distress syndrome: The Berlin Definition

COVID-19 pneumonia: ARDS or not?

Lung inhomogeneity in patients with acute respiratory distress syndrome

Relationship between ventilatory settings and barotrauma in the acute respiratory distress syndrome

Incidence of thrombotic complications in critically ill ICU patients with COVID-19

Predictors of pulmonary infarction

Pulmonary infarction secondary to pulmonary embolism: An evolving paradigm

Infected cavitating pulmonary infarction

The radiology of aseptic cavitation in pulmonary infarction

Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia